Project Grant HT94252310966
Award Date
9/30/23
Completion Date
9/29/26
Dollars Obligated
$3.8M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boulder, CO 80304, USA
Similar Awards
The U.S. Defense Health Agency awarded a $5,386,587 Project Grant (CFDA 12.420 - Military Medical Research and Development) to Cerulean Scientific Inc. on June 1, 2024. This grant supports the development of an "Omniphobic Cerebral Shunt to Eliminate Clogging and Dysfunction". Cerulean Scientific Inc., a small disadvantaged business manufacturer, will use the funding to conduct research and development on creating and optimizing tethered liquid perfluorocarbon (TLP) coatings for...
IHP Therapeutics Inc. was awarded a $217,928 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from March 2022 through September 2023 to develop a novel glycan therapeutic to treat Acute Respiratory Distress Syndrome. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research solutions. This award...
The U.S. Department of Defense, through the Military Medical Research and Development (CFDA 12.420) grant program, has awarded Nucyrna Therapeutics Inc. a $660,000 Project Grant to develop a SOD1-targeting iRNA oligonucleotide drug candidate with improved efficacy and safety compared to the existing drug tofersen. The grant, with a performance period from July 1, 2025 to June 30, 2027, aims to advance the development of this innovative therapeutic for military service members and the broader...
This federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $3,984,239.00 to Microvascular Therapeutics Inc. to conduct IND-enabling studies for targeted phase shift microbubbles for sonothrombolysis. The funding supports research and development activities by the for-profit biotechnology company to advance ultrasound contrast agent and delivery system technologies for diagnostic and...
The Defense Health Agency awarded Nushores Biosciences LLC a $582,000 Project Grant on February 15, 2025 under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports the development of an "Electrolysis Assisted Catalytic Oxygen Gas Generator for Battlefield Use". This project aims to create an innovative medical technology with direct applications in military environments to improve health outcomes for service members. The grant...
This $8.7 million project grant from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), supports the development of patient care technologies for permanent ambulatory artificial lung support from May 2022 to April 2026. Carnegie Mellon University is the primary awardee and will develop technologies to transition a pulmonary assist system to long-term support of chronic lung disease patients. Vanderbilt University Medical...
The Defense Health Agency awarded Epicentrx Inc. a $385,536 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program. The funding supports the development and translation of a multimodal therapeutic agent and medical countermeasure for the treatment of military-related toxic exposures. The project will be conducted over a 3-year period from September 1, 2024 to August 31, 2027. The research aims to transform healthcare for military service members and...
This $2,623,234 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports the development of a wearable multiplex biosensor system to monitor exacerbation risk in patients with chronic obstructive pulmonary disease (COPD). The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is the prime awardee, collaborating with researchers at the California Institute of Technology...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding an early-stage proof-of-concept study of a fixed-dose combination therapy in a high-fidelity porcine model of severe polytrauma. The $1,999,583 award to IRR Inc. in Santa Barbara, CA supports research focused on transforming healthcare for military service members and the broader public. The performance period runs from July 1, 2025 to June 30, 2027, with a...
This $305,917 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of an off-the-shelf reparative T regulatory cell (Treg) immunotherapy to limit tissue damage and initiate effective repair and resolution after lung injuries. The University of Pittsburgh, a major research institution, is the prime awardee on this 2-year grant with a performance period from December 1, 2023 to November 30,...